RRx-001, A novel dinitroazetidine radiosensitizer

Bryan Oronsky, Jan Scicinski, Shoucheng Ning, Donna Peehl, Arnold Oronsky, Pedro Cabrales, Mark Bednarski, Susan Knox

Research output: Contribution to journalReview articlepeer-review


The ‘holy grail’ in radiation oncology is to improve the outcome of radiation therapy (RT) with a radiosensitizer—a systemic chemical/biochemical agent that additively or synergistically sensitizes tumor cells to radiation in the absence of significant toxicity. Similar to the oxygen effect, in which DNA bases modified by reactive oxygen species prevent repair of the cellular radiation damage, these compounds in general magnify free radical formation, leading to the permanent “fixation” of the resultant chemical change in the DNA structure. The purpose of this review is to present the origin story of the radiosensitizer, RRx-001, which emerged from the aerospace industry. The activity of RRx-001 as a chemosensitizer in multiple tumor types and disease states including malaria, hemorrhagic shock and sickle cell anemia, are the subject of future reviews.

Original languageEnglish (US)
Pages (from-to)371-377
Number of pages7
JournalInvestigational New Drugs
Issue number3
StatePublished - Jun 1 2016


  • Cancer
  • Chemosensitizer
  • Clinical trials
  • RRx-001
  • Radiosensitization
  • Radiosensitizer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'RRx-001, A novel dinitroazetidine radiosensitizer'. Together they form a unique fingerprint.

Cite this